Neurimmune to receive a milestone payment from Ono Pharmaceuticals

18.09.2018 16:50
Neurimmune's Reverse Translational Medicine.

Last year, Neurimmune entered into a collaboration with the Japanese Ono Pharmaceuticals on the development of human-derived antibodies for the treatment of neurodegenerative diseases. The company has now achieved a key preclinical milestone, leading to a milestone payment.

Neurimmune develops innovative immunotherapeutics for human diseases. Its Reverse Translational Medicine (RTM) platform generates recombinant human monoclonal antibodies with unique therapeutic properties. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy.

In November 2017, the company signed a partnership with the Japanese based Ono Pharmaceuticals focused on the development of human-derived antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune would conduct research to generate and validate human-derived monoclonal antibodies using its RTM technology platform. The milestone triggers a pre-agreed milestone payment to Neurimmune.

“We highly appreciate a key success in drug discovery of human-derived monoclonal antibodies with Neurimmune’s platform”, said Hiromu Habashita, Corporate Officer and Executive Director, Discovery and Research of Ono. “We believe this progress will lead to the delivery of a novel and innovative treatment for patients with neurodegenerative diseases.”

“We highly value the collaborative nature of our partnership with Ono, a global pioneer of innovative medicines”, said Jan Grimm, Chief Scientific Officer and co-founder of Neurimmune. “We are excited about the rapid progress within the first year of this collaboration and look forward to advance novel human-derived antibody candidates for CNS indications of high unmet medical need.”

Ono will be responsible for worldwide development and marketing of products derived from this collaboration. Neurimmune is eligible to receive research fees, success-based milestones on the research and development progress, as well as royalties on product sales.

Photo: Neurimmune's Reverse Translational Medicine.

(Press release/ran)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

19.10.2018
Editorial

More openness to disruptive ideas

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.